Pharmaceuticals giant AbbVie is fighting to protect its blockbuster biologic Humira from challenges by lower-price competitors.
Drugmakers such as AbbVie and Valeant have been able to boost sales through direct-to-consumer advertising, but at what cost?
Hedge funds are using the Freedom of Information Act to generate legal, stock-moving information and alpha, reports a new study. But it’s not easy.
Buoyed by advances in genomics and a speedier FDA, health care investors are seeking moneymaking opportunities among pharmaceuticals companies developing expensive, new drugs.